The PI3Kδ inhibitor idelalisib inhibits homing in an in vitro and in vivo model of B ALL

Etai Adam, Hye Na Kim, Eun Ji Gang, Caitlin Schnair, Solomon Lee, Solah Lee, Sajad Khazal, Osanna Kosoyan, Marina Konopleva, Chintan Parekh, Deepa Bhojwani, Alan S. Wayne, Hisham Abdel-Azim, Nora Heisterkamp, Yong Mi Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The quest continues for targeted therapies to reduce the morbidity of chemotherapy and to improve the response of resistant leukemia. Adhesion of acute lymphoblastic leukemia (ALL) cells to bone marrow stromal cells triggers intracellular signals that promote cell-adhesion-mediated drug resistance (CAM-DR). Idelalisib, an U.S. Food and Drug Administration (FDA)-approved PI3Kδ-specific inhibitor has been shown to be effective in CLL in down-regulating p-Akt and prolonging survival in combination with Rituximab; herein we explore the possibility of its use in B ALL and probe the mechanism of action. Primary B ALL in contact with OP9 stromal cells showed increased p-Aktser473. Idelalisib decreased p-Akt in patient samples of ALL with diverse genetic lesions. Addition of idelalisib to vincristine inhibited proliferation when compared to vincristine monotherapy in a subset of samples tested. Idelalisib inhibited ALL migration to SDF-1α in vitro and blocked homing of ALL cells to the bone marrow in vivo. This report tests PI3Kδ inhibitors in a more diverse group of ALL than has been previously reported and is the first published report of idelalisib inhibiting homing of ALL cells to bone marrow. Our data support further pre-clinical evaluation of idelalisib for the therapy of B ALL.

Original languageEnglish (US)
Article number121
JournalCancers
Volume9
Issue number9
DOIs
StatePublished - Sep 10 2017
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinases
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Vincristine
Bone Marrow Cells
idelalisib
In Vitro Techniques
United States Food and Drug Administration
Stromal Cells
Mesenchymal Stromal Cells
Drug Resistance
Cell Adhesion
Leukemia
Morbidity
Drug Therapy
Survival
Therapeutics

Keywords

  • ALL
  • CAM-DR
  • Drug resistance
  • Idelalisib
  • Leukemia
  • Migration
  • Mouse model
  • PI3K

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adam, E., Kim, H. N., Gang, E. J., Schnair, C., Lee, S., Lee, S., ... Kim, Y. M. (2017). The PI3Kδ inhibitor idelalisib inhibits homing in an in vitro and in vivo model of B ALL. Cancers, 9(9), [121]. https://doi.org/10.3390/cancers9090121

The PI3Kδ inhibitor idelalisib inhibits homing in an in vitro and in vivo model of B ALL. / Adam, Etai; Kim, Hye Na; Gang, Eun Ji; Schnair, Caitlin; Lee, Solomon; Lee, Solah; Khazal, Sajad; Kosoyan, Osanna; Konopleva, Marina; Parekh, Chintan; Bhojwani, Deepa; Wayne, Alan S.; Abdel-Azim, Hisham; Heisterkamp, Nora; Kim, Yong Mi.

In: Cancers, Vol. 9, No. 9, 121, 10.09.2017.

Research output: Contribution to journalArticle

Adam, E, Kim, HN, Gang, EJ, Schnair, C, Lee, S, Lee, S, Khazal, S, Kosoyan, O, Konopleva, M, Parekh, C, Bhojwani, D, Wayne, AS, Abdel-Azim, H, Heisterkamp, N & Kim, YM 2017, 'The PI3Kδ inhibitor idelalisib inhibits homing in an in vitro and in vivo model of B ALL', Cancers, vol. 9, no. 9, 121. https://doi.org/10.3390/cancers9090121
Adam, Etai ; Kim, Hye Na ; Gang, Eun Ji ; Schnair, Caitlin ; Lee, Solomon ; Lee, Solah ; Khazal, Sajad ; Kosoyan, Osanna ; Konopleva, Marina ; Parekh, Chintan ; Bhojwani, Deepa ; Wayne, Alan S. ; Abdel-Azim, Hisham ; Heisterkamp, Nora ; Kim, Yong Mi. / The PI3Kδ inhibitor idelalisib inhibits homing in an in vitro and in vivo model of B ALL. In: Cancers. 2017 ; Vol. 9, No. 9.
@article{1a17b158b5d941e784dd5e6f65672193,
title = "The PI3Kδ inhibitor idelalisib inhibits homing in an in vitro and in vivo model of B ALL",
abstract = "The quest continues for targeted therapies to reduce the morbidity of chemotherapy and to improve the response of resistant leukemia. Adhesion of acute lymphoblastic leukemia (ALL) cells to bone marrow stromal cells triggers intracellular signals that promote cell-adhesion-mediated drug resistance (CAM-DR). Idelalisib, an U.S. Food and Drug Administration (FDA)-approved PI3Kδ-specific inhibitor has been shown to be effective in CLL in down-regulating p-Akt and prolonging survival in combination with Rituximab; herein we explore the possibility of its use in B ALL and probe the mechanism of action. Primary B ALL in contact with OP9 stromal cells showed increased p-Aktser473. Idelalisib decreased p-Akt in patient samples of ALL with diverse genetic lesions. Addition of idelalisib to vincristine inhibited proliferation when compared to vincristine monotherapy in a subset of samples tested. Idelalisib inhibited ALL migration to SDF-1α in vitro and blocked homing of ALL cells to the bone marrow in vivo. This report tests PI3Kδ inhibitors in a more diverse group of ALL than has been previously reported and is the first published report of idelalisib inhibiting homing of ALL cells to bone marrow. Our data support further pre-clinical evaluation of idelalisib for the therapy of B ALL.",
keywords = "ALL, CAM-DR, Drug resistance, Idelalisib, Leukemia, Migration, Mouse model, PI3K",
author = "Etai Adam and Kim, {Hye Na} and Gang, {Eun Ji} and Caitlin Schnair and Solomon Lee and Solah Lee and Sajad Khazal and Osanna Kosoyan and Marina Konopleva and Chintan Parekh and Deepa Bhojwani and Wayne, {Alan S.} and Hisham Abdel-Azim and Nora Heisterkamp and Kim, {Yong Mi}",
year = "2017",
month = "9",
day = "10",
doi = "10.3390/cancers9090121",
language = "English (US)",
volume = "9",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",

}

TY - JOUR

T1 - The PI3Kδ inhibitor idelalisib inhibits homing in an in vitro and in vivo model of B ALL

AU - Adam, Etai

AU - Kim, Hye Na

AU - Gang, Eun Ji

AU - Schnair, Caitlin

AU - Lee, Solomon

AU - Lee, Solah

AU - Khazal, Sajad

AU - Kosoyan, Osanna

AU - Konopleva, Marina

AU - Parekh, Chintan

AU - Bhojwani, Deepa

AU - Wayne, Alan S.

AU - Abdel-Azim, Hisham

AU - Heisterkamp, Nora

AU - Kim, Yong Mi

PY - 2017/9/10

Y1 - 2017/9/10

N2 - The quest continues for targeted therapies to reduce the morbidity of chemotherapy and to improve the response of resistant leukemia. Adhesion of acute lymphoblastic leukemia (ALL) cells to bone marrow stromal cells triggers intracellular signals that promote cell-adhesion-mediated drug resistance (CAM-DR). Idelalisib, an U.S. Food and Drug Administration (FDA)-approved PI3Kδ-specific inhibitor has been shown to be effective in CLL in down-regulating p-Akt and prolonging survival in combination with Rituximab; herein we explore the possibility of its use in B ALL and probe the mechanism of action. Primary B ALL in contact with OP9 stromal cells showed increased p-Aktser473. Idelalisib decreased p-Akt in patient samples of ALL with diverse genetic lesions. Addition of idelalisib to vincristine inhibited proliferation when compared to vincristine monotherapy in a subset of samples tested. Idelalisib inhibited ALL migration to SDF-1α in vitro and blocked homing of ALL cells to the bone marrow in vivo. This report tests PI3Kδ inhibitors in a more diverse group of ALL than has been previously reported and is the first published report of idelalisib inhibiting homing of ALL cells to bone marrow. Our data support further pre-clinical evaluation of idelalisib for the therapy of B ALL.

AB - The quest continues for targeted therapies to reduce the morbidity of chemotherapy and to improve the response of resistant leukemia. Adhesion of acute lymphoblastic leukemia (ALL) cells to bone marrow stromal cells triggers intracellular signals that promote cell-adhesion-mediated drug resistance (CAM-DR). Idelalisib, an U.S. Food and Drug Administration (FDA)-approved PI3Kδ-specific inhibitor has been shown to be effective in CLL in down-regulating p-Akt and prolonging survival in combination with Rituximab; herein we explore the possibility of its use in B ALL and probe the mechanism of action. Primary B ALL in contact with OP9 stromal cells showed increased p-Aktser473. Idelalisib decreased p-Akt in patient samples of ALL with diverse genetic lesions. Addition of idelalisib to vincristine inhibited proliferation when compared to vincristine monotherapy in a subset of samples tested. Idelalisib inhibited ALL migration to SDF-1α in vitro and blocked homing of ALL cells to the bone marrow in vivo. This report tests PI3Kδ inhibitors in a more diverse group of ALL than has been previously reported and is the first published report of idelalisib inhibiting homing of ALL cells to bone marrow. Our data support further pre-clinical evaluation of idelalisib for the therapy of B ALL.

KW - ALL

KW - CAM-DR

KW - Drug resistance

KW - Idelalisib

KW - Leukemia

KW - Migration

KW - Mouse model

KW - PI3K

UR - http://www.scopus.com/inward/record.url?scp=85029456219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029456219&partnerID=8YFLogxK

U2 - 10.3390/cancers9090121

DO - 10.3390/cancers9090121

M3 - Article

VL - 9

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 9

M1 - 121

ER -